Patents by Inventor Jordan Dubow

Jordan Dubow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11896572
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: February 13, 2024
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20230381131
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Application
    Filed: August 8, 2023
    Publication date: November 30, 2023
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11826335
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: November 28, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11779557
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: October 10, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Cendrine Grangeon, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11766418
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: September 26, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20230210804
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Application
    Filed: March 10, 2023
    Publication date: July 6, 2023
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20230172893
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Application
    Filed: January 12, 2023
    Publication date: June 8, 2023
    Inventors: Jordan DUBOW, Hervé GUILLARD, Claire Mégret, Jean-François DUBUISSON
  • MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
    Publication number: 20230172892
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 8, 2023
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11602512
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
    Patent number: 11602513
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20220313635
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: June 10, 2022
    Publication date: October 6, 2022
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
    Patent number: 11400065
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: August 2, 2022
    Assignee: Flamel Ireland Limited
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA
    Publication number: 20210205208
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Application
    Filed: February 18, 2021
    Publication date: July 8, 2021
    Inventors: Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
  • Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
    Patent number: 10959943
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 30, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo
  • Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
    Patent number: 10925844
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: February 23, 2021
    Assignee: Flamel Ireland Limited
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20200368187
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20200360319
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE
    Publication number: 20200276142
    Abstract: Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 3, 2020
    Inventors: Julien Grassot, Cendrine Grangeon, Jordan Dubow
  • METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA
    Publication number: 20200069571
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 5, 2020
    Inventors: Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
  • Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
    Patent number: 10449146
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: October 22, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo